For the quarter ending 2025-09-30, FBIOP had $11,832K increase in cash & cash equivalents over the period.
| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net income (loss) | -27,518 | - |
| Depreciation expense | 93 | 218 |
| Loss on disposal of property and equipment | 0 | 0 |
| Bad debt (recovery) expense | 76 | -246 |
| Amortization of debt discount | 319 | 746 |
| Accretion of partner company convertible preferred shares | 0 | 0 |
| Gain on termination of partner company lease | 0 | 394 |
| Loss on extinguishment of debt | 0 | - |
| Amortization of acquired intangible assets | 3,193 | - |
| Settlement of partner company payables | -577 | -796 |
| Reduction in the carrying amount of operating lease right-of-use assets | 496 | 971 |
| Stock-based compensation expense | 3,198 | 23,082 |
| Change in fair value of investment | 15,075 | - |
| Expense (income) associated with warrant liabilities | 2 | 397 |
| Common shares issued for dividend on partner company's convertible preferred shares | 0 | 0 |
| Gain from deconsolidation of subsidiary | 27,127 | - |
| Asset impairment loss | 0 | 0 |
| Accounts receivable | 2,415 | 5,167 |
| Inventory | -1,034 | -1,579 |
| Other receivables - related party | -416 | 387 |
| Prepaid expenses and other current assets | -1,744 | -2,355 |
| Other assets | -17 | -292 |
| Accounts payable and accrued expenses | -2,828 | -7,821 |
| Income taxes payable | 21 | 52 |
| Lease liabilities | -549 | -1,125 |
| Other liabilities | -1,973 | 464 |
| Net cash used in operating activities | -6,110 | -47,123 |
| Proceeds from sale of property and equipment | 0 | 1,165 |
| Proceeds from sale of subsidiary interests | - | 6,086 |
| Net cash increase upon deconsolidation of subsidiary | 8,956 | - |
| Net cash provided by investing activities | 2,870 | 7,251 |
| Payment of series a perpetual preferred stock dividends | 0 | 0 |
| Proceeds from issuance of common stock for public offering, net | 0 | 0 |
| Proceeds from issuance of common stock for at-the-market offering, net | 0 | 1,008 |
| Proceeds from issuance of common stock under espp | 0 | 43 |
| Exercise of warrants for cash | 1,686 | 593 |
| Proceeds from partner companies' espp | 118 | 99 |
| Partner company's dividends declared and paid | 166 | 332 |
| Partner company's redemption of preferred shares | 0 | 265 |
| Proceeds from partner companies' equity offerings, options and warrant exercises, net | 7,247 | 54,334 |
| Proceeds from partner companies' at-the-market offering, net | 6,891 | 6,740 |
| Repayment of oaktree note | 574 | 4,932 |
| Repayment of partner company installment payments - licenses | 0 | 625 |
| Stock and warrants issued for exchange of partner company preferred shares | 0 | 0 |
| Proceeds from long-term debt, net | -130 | - |
| Proceeds from partner company's long-term debt, net | 0 | 0 |
| Net cash provided by financing activities | 15,072 | 56,663 |
| Net increase in cash and cash equivalents and restricted cash | 11,832 | 16,791 |
| Cash and cash equivalents at beginning of period | 58,815 | - |
| Cash and cash equivalents at end of period | 87,438 | - |
Fortress Biotech, Inc. (FBIOP)
Fortress Biotech, Inc. (FBIOP)